Why Norgine’s PEDMARQSI approval in Switzerland could reshape cisplatin ototoxicity management
Swissmedic approved PEDMARQSI for cisplatin-related hearing loss in children. Read why this could reshape paediatric oncology supportive care.
Can Assertio win market traction with convenience-led G-CSF dosing schedules?
Can same-day dosing of Rolvedon reduce burden in breast cancer care? Explore new trial data, regulatory risks, and clinical impact in this detailed analysis.